GENETICALLY-DETERMINED ADVERSE DRUG-REACTIONS INVOLVING METABOLISM

被引:28
作者
LENNARD, MS
机构
[1] Department of Medicine and Pharmacology, University of Sheffield, Royal Hallamshire Hospital, Sheffield
[2] University Department of Medicine and Therapeutics, Section of Pharmacology and Therapeutics, Royal Hallamshire Hospital, Sheffield, S10 2JF, Floor L, Glossop Road
关键词
D O I
10.2165/00002018-199309010-00006
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Genetic factors represent an important source of interindividual variation in drug response. Relatively few adverse drug effects with a pharmacodynamic basis are known, and most of the well characterised inherited traits take the form of genetic polymorphisms of drug metabolism. Monogenic control of N-acetylation. S-methylation and cytochrome P450-catalysed oxidation of drugs can have important clinical consequences. Individuals who inherit an impaired ability to perform one or more of these reactions may be at an increased risk of concentration-related toxicity. There is a strong case for phenotyping before starting treatment with a small number of drugs that are polymorphically N-acetylated or S-methylated. However, the issue of clinical significance is perhaps most relevant for the debrisoquine oxidation polymorphism, which is mediated by cytochrome CYP2D6 and which determines the pharmacokinetics of many commonly used drugs. Phenotypic poor metabolisers of debrisoquine (8% of Caucasian populations) taking standard doses of some tricyclic antidepressants, neuroleptics or antiarrhythmic drugs may be particularly prone to adverse reactions. Similarly, clinically relevant drug interactions between these drugs and other substrates of cytochrome CYP2D6 may occur in the majority of the population who are extensive metabolisers. However, it is clear that in the majority of cases there is a need for controlled prospective studies to determine clinical significance. Accordingly, routine debrisoquine phenotyping or geno-typing before beginning drug treatment is difficult to justify at present, although it may be helpful in individual cases. When prescribing drugs whose metabolism is polymorphic alone or in combination, careful titration of the dose in both phenotypic groups is prudent. In some cases it will be preferable to use alternative therapy to avoid the risk of adverse drug reactions.
引用
收藏
页码:60 / 77
页数:18
相关论文
共 143 条
[11]  
Bloomer J.C., Woods F.R., Haddock R.E., Lennard, Tucker G.T., The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes, British Journal of Clinical Pharmacology, 33, pp. 521-523, (1992)
[12]  
Bluhm R.E., Wilkinson G.R., Shelton R., Branch R.A., Genetically determined drug-metabolizing activity and desipramine associated cardiotoxicity: a case report, Clinical Pharmacology and Therapeutics, 53, pp. 89-95, (1993)
[13]  
Brockmoller J., Staffeldt B., Roots I., Evaluation of proposed sulphoxidation pathways of carbocysteine in man by HPLC quantification, European Journal of Clinical Pharmacology, 40, pp. 387-392, (1991)
[14]  
Broly F., Libersa C., Lhermitte M., Dupuis B., Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes, Biochemical Pharmacology, 39, pp. 1045-1053, (1990)
[15]  
Broly F., Vandamme N., Libersa C., Lhermitte M., The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation, British Journal of Clinical Pharmacology, 32, pp. 459-466, (1991)
[16]  
Brosen K., Gram L.F., Clinical significance of the sparteine/debrisoquine oxidation polymorphism, European Journal of Clinical Pharmacology, 36, pp. 537-547, (1989)
[17]  
Brosen K., Gram L.F., Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine, European Journal of Clinical Pharmacology, 37, pp. 155-160, (1989)
[18]  
Buchert E., Woosley R.L., Clinical implications of variable antiarrhythmic drug metabolism, Pharmacogenetics, 2, pp. 2-11, (1992)
[19]  
Burchill B., Coughtrie M.W.H., UDP-Glucuronyltransferases, Pharmacology and Therapeutics, 43, pp. 261-289, (1989)
[20]  
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arryhthmia suppression after myocardial infarction, New England Journal of Medicine, 321, pp. 406-412, (1989)